Annual Cash & Cash Equivalents
$32.55 M
-$684.00 K-2.06%
December 31, 2021
Summary
- As of February 10, 2025, IDRA annual cash & cash equivalents is $32.55 million, with the most recent change of -$684.00 thousand (-2.06%) on December 31, 2021.
- During the last 3 years, IDRA annual cash & cash equivalents has fallen by -$38.89 million (-54.44%).
Performance
IDRA Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$26.80 M
+$2.31 M+9.46%
September 30, 2022
Summary
- As of February 10, 2025, IDRA quarterly cash and cash equivalents is $26.80 million, with the most recent change of +$2.31 million (+9.46%) on September 30, 2022.
- Over the past year, IDRA quarterly cash and cash equivalents has dropped by -$9.81 million (-26.79%).
Performance
IDRA Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
IDRA Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -2.1% | -26.8% |
| 3 y3 years | -54.4% | -17.8% |
| 5 y5 years | -71.1% | -58.1% |
IDRA Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | at low | -17.7% | -8.6% |
| 5 y | 5-year | -18.7% | at low | -39.8% | -16.7% |
| alltime | all time | -71.1% | -97.0% | -76.2% | -98.8% |
Idera Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $26.80 M(+9.5%) |
| Jun 2022 | - | $24.48 M(-12.5%) |
| Mar 2022 | - | $27.99 M(-14.0%) |
| Dec 2021 | $32.55 M(-2.1%) | $32.55 M(-11.1%) |
| Sep 2021 | - | $36.60 M(-9.8%) |
| Jun 2021 | - | $40.59 M(-8.9%) |
| Mar 2021 | - | $44.54 M(+34.0%) |
| Dec 2020 | $33.23 M(-17.0%) | $33.23 M(+48.8%) |
| Sep 2020 | - | $22.33 M(-19.7%) |
| Jun 2020 | - | $27.81 M(-0.4%) |
| Mar 2020 | - | $27.91 M(-30.3%) |
| Dec 2019 | $40.02 M(-44.0%) | $40.02 M(+22.7%) |
| Sep 2019 | - | $32.61 M(-18.2%) |
| Jun 2019 | - | $39.88 M(+64.8%) |
| Mar 2019 | - | $24.20 M(-66.1%) |
| Dec 2018 | $71.43 M(-36.6%) | $71.43 M(-13.4%) |
| Sep 2018 | - | $82.46 M(-12.3%) |
| Jun 2018 | - | $94.05 M(-12.5%) |
| Mar 2018 | - | $107.46 M(-4.6%) |
| Dec 2017 | $112.63 M(+39.6%) | $112.63 M(+76.1%) |
| Sep 2017 | - | $63.94 M(-14.4%) |
| Jun 2017 | - | $74.66 M(-6.3%) |
| Mar 2017 | - | $79.69 M(-1.2%) |
| Dec 2016 | $80.67 M(+203.4%) | $80.67 M(+264.1%) |
| Sep 2016 | - | $22.15 M(-7.9%) |
| Jun 2016 | - | $24.06 M(+10.0%) |
| Mar 2016 | - | $21.88 M(-17.7%) |
| Dec 2015 | $26.59 M(+33.1%) | $26.59 M(-5.0%) |
| Sep 2015 | - | $28.00 M(-23.0%) |
| Jun 2015 | - | $36.37 M(-60.6%) |
| Mar 2015 | - | $92.27 M(+362.0%) |
| Dec 2014 | $19.97 M(-24.0%) | $19.97 M(-58.8%) |
| Sep 2014 | - | $48.49 M(-11.7%) |
| Jun 2014 | - | $54.89 M(-9.6%) |
| Mar 2014 | - | $60.75 M(+131.2%) |
| Dec 2013 | $26.28 M(+160.3%) | $26.28 M(-32.2%) |
| Sep 2013 | - | $38.75 M(+137.7%) |
| Jun 2013 | - | $16.30 M(+165.1%) |
| Mar 2013 | - | $6.15 M(-39.1%) |
| Dec 2012 | $10.10 M(-58.9%) | $10.10 M(+20.9%) |
| Sep 2012 | - | $8.35 M(-36.9%) |
| Jun 2012 | - | $13.23 M(-29.2%) |
| Mar 2012 | - | $18.69 M(-23.9%) |
| Dec 2011 | $24.57 M(+44.5%) | $24.57 M(+35.9%) |
| Sep 2011 | - | $18.08 M(-15.9%) |
| Jun 2011 | - | $21.49 M(+1.8%) |
| Mar 2011 | - | $21.11 M(+24.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2010 | $17.01 M(-33.2%) | $17.01 M(-15.2%) |
| Sep 2010 | - | $20.05 M(+104.3%) |
| Jun 2010 | - | $9.82 M(-33.8%) |
| Mar 2010 | - | $14.84 M(-41.8%) |
| Dec 2009 | $25.47 M(-43.6%) | $25.47 M(-40.3%) |
| Sep 2009 | - | $42.66 M(-11.5%) |
| Jun 2009 | - | $48.22 M(+2.3%) |
| Mar 2009 | - | $47.13 M(+4.4%) |
| Dec 2008 | $45.16 M(+258.8%) | $45.16 M(+17.3%) |
| Sep 2008 | - | $38.52 M(-20.6%) |
| Jun 2008 | - | $48.53 M(-6.0%) |
| Mar 2008 | - | $51.62 M(+310.1%) |
| Dec 2007 | $12.59 M(-48.8%) | $12.59 M(+5.2%) |
| Sep 2007 | - | $11.96 M(+90.3%) |
| Jun 2007 | - | $6.29 M(+80.5%) |
| Mar 2007 | - | $3.48 M(-85.8%) |
| Dec 2006 | $24.60 M(+2397.6%) | $24.60 M(+1294.3%) |
| Sep 2006 | - | $1.76 M(-13.8%) |
| Jun 2006 | - | $2.05 M(-73.1%) |
| Mar 2006 | - | $7.61 M(+673.1%) |
| Dec 2005 | $984.80 K(-80.4%) | $984.80 K(-81.9%) |
| Sep 2005 | - | $5.44 M(+35.0%) |
| Jun 2005 | - | $4.03 M(+9.1%) |
| Mar 2005 | - | $3.70 M(-26.4%) |
| Dec 2004 | $5.02 M(-34.0%) | $5.02 M(-38.9%) |
| Sep 2004 | - | $8.22 M(+411.4%) |
| Jun 2004 | - | $1.61 M(-15.5%) |
| Mar 2004 | - | $1.90 M(-75.0%) |
| Dec 2003 | $7.61 M(+68.0%) | $7.61 M(-55.8%) |
| Sep 2003 | - | $17.21 M(+124.3%) |
| Jun 2003 | - | $7.67 M(+71.3%) |
| Mar 2003 | - | $4.48 M(-1.1%) |
| Dec 2002 | $4.53 M(-78.4%) | $4.53 M(-28.6%) |
| Sep 2002 | - | $6.34 M(-27.7%) |
| Jun 2002 | - | $8.77 M(-22.7%) |
| Mar 2002 | - | $11.35 M(-45.8%) |
| Dec 2001 | $20.92 M(+1265.6%) | $20.92 M(+147.8%) |
| Sep 2001 | - | $8.44 M(-33.7%) |
| Jun 2001 | - | $12.74 M(+103.2%) |
| Mar 2001 | - | $6.27 M(+309.2%) |
| Dec 2000 | $1.53 M(-41.1%) | $1.53 M(-70.7%) |
| Sep 2000 | - | $5.24 M(+1588.6%) |
| Jun 2000 | - | $310.10 K(-82.7%) |
| Mar 2000 | - | $1.80 M |
| Dec 1999 | $2.60 M(-53.6%) | - |
| Dec 1998 | $5.61 M(+154.6%) | - |
| Dec 1997 | $2.20 M(-82.6%) | - |
| Dec 1996 | $12.63 M | - |
FAQ
- What is Idera Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Idera Pharmaceuticals?
- What is Idera Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Idera Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Idera Pharmaceuticals?
- What is Idera Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is Idera Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of IDRA is $32.55 M
What is the all time high annual cash & cash equivalents for Idera Pharmaceuticals?
Idera Pharmaceuticals all-time high annual cash & cash equivalents is $112.63 M
What is Idera Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, IDRA annual cash & cash equivalents has changed by -$684.00 K (-2.06%)
What is Idera Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of IDRA is $26.80 M
What is the all time high quarterly cash and cash equivalents for Idera Pharmaceuticals?
Idera Pharmaceuticals all-time high quarterly cash and cash equivalents is $112.63 M
What is Idera Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, IDRA quarterly cash and cash equivalents has changed by -$9.81 M (-26.79%)